NO produced by eNOS (endothelial nitric oxide synthase) is a key mediator of vascular homoeostasis. NO bioavailability is reduced early in vascular disease states, such as hypercholesterolaemia, diabetes and hypertension, and throughout the progression of atherosclerosis. This is a result of both reduced NO synthesis and increased NO consumption by reactive oxygen species. eNOS enzymatic activity appears to be determined by the availability of its cofactor BH4 (tetrahydrobiopterin). When BH4 levels are adequate, eNOS produces NO; when BH4 levels are limiting, eNOS becomes enzymatically uncoupled and generates superoxide, contributing to vascular oxidative stress and endothelial dysfunction. BH4 bioavailability is determined by a balance of enzymatic de novo synthesis and recycling, versus oxidative degradation in dysfunctional endothelium. Augmenting vascular BH4 levels by pharmacological supplementation, by enhancing the rate of de novo biosynthesis or by measures to reduce BH4 oxidation have been shown in experimental studies to enhance NO bioavailability. Thus BH4 represents a potential therapeutic target for preserving eNOS function in vascular disease.
INTRODUCTION
Vascular diseases, such as coronary artery disease, stroke and peripheral arterial disease, remain the largest causes of mortality and morbidity in industrialized countries and will continue to impose a major burden on health care resources. An early feature of all vascular disease states and risk factor syndromes is abnormal endothelial function, resulting in loss of normal homoeostatic pathways that act to inhibit disease processes such as inflammation, thrombosis and oxidative stress [1, 2] . One critical aspect of normal endothelial function is the production of NO by eNOS [endothelial NOS (nitric oxide synthase)]. Through downstream signalling pathways, NO modulates vasomotor tone and has a number of important anti-atherogenic effects on platelets and vascular smooth muscle and endothelial cells [3] .
In humans, endothelial function is altered in subjects with vascular disease states and correlates with risk factor profile [1, 4] . Importantly, several prospective studies have now identified deficient NO-mediated endothelial function as a quantitative independent predictor of adverse cardiac events [5] [6] [7] [8] . Numerous animal model studies have contributed further strong evidence that NO, generated by eNOS, has key roles in vascular disease pathogenesis (reviewed in [9] ).
Despite the central role of eNOS and eNOS-derived NO in vascular homoeostasis, therapeutic strategies attempting to restore or augment NO production in disease states have been largely disappointing. Short-term overexpression of NOS can increase NO production, acutely improve NO-mediated endothelial function and reduce inflammatory cell recruitment [10] . However, eNOS protein levels are increased, rather than decreased, in disease states such as diabetes, yet NO bioavailability remains reduced. Furthermore, long-term transgenic overexpression of eNOS in the ApoE-KO (apolipoprotein E knockout) mouse model of atherosclerosis paradoxically accelerates plaque formation [11] . Thus reductions in NO bioactivity in vascular disease are not explained simply by loss of eNOS protein and, indeed, plentiful eNOS protein is no guarantee of adequate NO bioavailability. Clinical drug therapies that reduce longterm cardiovascular risk through targeting known risk factors also improve NO-mediated endothelial function. However, simple strategies aimed at pharmacological NO generation, such as the use of nitrate drugs, have shown no prognostic clinical benefits and are paradoxically associated with adverse consequences such as impaired vasomotor responses and increased vascular oxidative stress [12] .
The discordance between the clear biological rationale for eNOS as a therapeutic target compared with the disappointing translation into clinical benefit has been related to an incomplete understanding of the mechanistic aspects of eNOS regulation in vascular disease pathophysiology. In particular, emerging data on the role of the NOS cofactor BH4 (tetrahydrobiopterin) in regulating eNOS function have provided insights that point to new therapeutic strategies. This review will address the mechanistic importance of BH4 bioavailability in regulating eNOS in vascular disease.
NO IN VASCULAR HOMOEOSTASIS AND VASCULAR DISEASE
In 1980, Furchgott and Zawadzki [13] discovered that vascular segments with an intact endothelium were able to relax in response to stimulation by acetylcholine. The vascular relaxation was dependent on the presence of endothelial cells, which released a diffusible, labile, non-prostanoid substance, termed EDRF (endotheliumderived relaxing factor), which acted on vascular smooth muscle to produce relaxation. In 1987, Ignarro's and Moncada's groups [14, 15] demonstrated independently that EDRF was NO. Subsequently, Moncada and coworkers [16] showed further that NO is synthesized from the oxidation of l-arginine, mediated in a two-step process by the NOSs (EC 1.14.13.39) via the formation of N-hydroxyl l-arginine [17] .
NO diffuses locally within the endothelial cell itself, to the luminal surface of the endothelium, and into the smooth muscle cells of the vascular wall, where it signals diverse downstream pathways through activation of guanylate cyclase to generate cGMP, and by direct S-nitrosylation of cysteine residues in various proteins, including transcription factors such as NF-κB (nuclear factor κB) [18] .
The first NOS enzyme was isolated from brain [19] , which determined its name neuronal or nNOS (also known as NOS1). nNOS has subsequently been shown to be constitutively expressed in a variety of cells, including endothelial cells and neurons [20] . The inducible isoform of NOS (iNOS; NOS2) was subsequently isolated from macrophages [21] , but iNOS expression has been reported in numerous cell lines after exposure to cytokines [22, 23] . The third member of the family, eNOS (NOS3), was initially isolated from bovine aortic endothelial cells [24] . In endothelial cells, eNOS is subject to rapid changes in activity, regulated by signalling molecules integrated in caveolae. Receptor-mediated agonist stimulation leads to rapid enzyme activation by the binding of calcium/calmodulin, depalmitoylation of eNOS, displacement of caveolin-1 and release of eNOS from caveolae [25, 26] . Changes in eNOS activity are also mediated through phosphorylation of key residues. Aktdependent phosphorylation at Ser 1177 activates eNOS in response to stimuli such as fluid shear stress, oestrogen and insulin [27] , whereas phosphorylation at Thr
459
[for example, by PKC (protein kinase C)] reduces activation. Dephosphorylation of Thr 459 by PP1 (protein phosphatase 1) contributes to eNOS activation in response to bradykinin [28] . Although eNOS is constitutively expressed in endothelial cells, eNOS gene transcription may be modulated by a variety of factors. For example, laminar shear stress is an important stimulus in maintaining or up-regulating eNOS expression [29, 30] . eNOS protein levels may be reduced in endothelial cells overlying advanced atherosclerotic plaques [31] , but eNOS protein may remain normal or even increase, despite marked endothelial dysfunction, in pre-atherosclerotic states such as diabetes [32, 33] , experimental heart failure [34] and hypertension [35] . These findings have led to the concept of 'eNOS uncoupling', characterized by the discrepancy between eNOS protein levels and NO production and, indeed, a switch in the enzymatic activity of eNOS to generate superoxide rather than NO. Accumulating evidence points towards a crucial role of the pterin cofactor BH4 in the regulation of eNOS function, specifically by modulating the enzymatic activity of NOS.
BH4
The pterins were first described by Hopkins in 1895 [36] , then characterized by Watt in the 1960s [37] . BH4 was initially identified as a cofactor for phenylalanine hydroxylase (EC 1.14.16.1), and the other aromatic amino acid hydroxylases tyrosine 3-hydroxylase (EC 1.14.16.2) and tryptophan 5-hydroxylase (EC 1.14.16.4). In 1989, BH4 was identified as a required cofactor for the NOS enzymes by Stuehr and co-workers [38] and Tayeh and Marletta [39] .
Synthetic pathways
BH4 biosynthesis proceeds via the de novo pathway in a magnesium-, zinc-and NADPH-dependent reaction from GTP via the two intermediates 7,8-dihydroneopterin triphosphate and 6-pyruvoyl-5,6,7,8-tetrahydropterin (reviewed in [40] ) (Figure 1) . In endothelial cells, the first and rate-limiting step in this pathway is GTPCH (GTP cyclohydrolase I; EC 3.5.4.16). The subsequent steps are catalysed by the enzymes PTPS (6-pyruvoyltetrahydropterin synthase; EC 4.2.3.12) and SR (sepiapterin reductase; EC 1.1.1.153).
As the rate-limiting enzyme for BH4 synthesis, GTPCH regulation takes place at transcriptional and post-transcriptional levels. Cytokines, including IFN-γ (interferon-γ ) and TNF-α (tumour necrosis factor-α), transcription factors NF-κB and STAT1/3 (signal transducer and activator of transcription 1/3) as well as inflammatory mediators, such as LPS (lipopolysaccharides), are reported to increase GTPCH transcription [41] [42] [43] , enzyme activity [44] and BH4 levels in human endothelial cells.
The proximal promoter of the human GCH1 gene (encoding GTPCH) contains a sequence motif resembling a CRE (cAMP-response element), which indicates potential transcriptional regulation by bZIP (basic region leucine zipper) transcription factors. To examine this putative interaction, Al Sarraj et al. [45] used constitutively active and dominant-negative bZIP transcription factor mutants and measured transcriptional activation of a GCH1 promoter/luciferase reporter gene. Signalling pathways involving either PKA (cAMP-dependent protein kinase) or SAPKs (stress-activated protein kinases) converged to the GCH1 gene, indicating that enzymatic reactions requiring BH4 as a cofactor are indirectly controlled by signalling cascades involving the transcription factors CREB (CRE-binding protein), c-Jun and ATF2 (activating transcription factor 2) [45] . Insulin may also up-regulate GTPCH expression in endothelial cells via a PI3K (phosphoinositide 3-kinase)-dependent pathway [46] . GTPCH is also subject to post-translational modification by phosphorylation. In rat mesangial cells, AngII (angiotensin II) and PDGF (platelet-derived growth factor) are reported to increase GTPCH activity by phosphorylation via a PKC-dependent mechanism [47] . However, the role of GTPCH phosphorylation in endothelial cells has not been determined. Finally, GTPCH activity is governed by interactions with GFRP (GTPCH feedback regulatory protein), which has been cloned and purified [48] and is a homopentamer of 52 kDa subunits [49, 50] . Recently, X-ray crystallography unveiled the nature of the physical interaction between GFRP and GTPCH [51, 52] . Through GFRP, phenylalanine exerts positive regulation of GTPCH activity, and BH4 exhibits negative feedback regulation [53] . Structural analysis revealed that five BH4 molecules are located at each interface between GTPCH and GFRP. BH4 binding induces large conformational changes in GTPCH peptide segments forming the active site, resulting in inhibition of enzymatic activity [54] .
GFRP expression has been documented in various cell types and is highly expressed in hepatocytes [48] . First indications about its biological relevance in endothelial cells came from a study by Ishii et al. [55] , using cultured endothelial cells to examine the effect of H 2 O 2 on the expression of GFRP. Addition of H 2 O 2 to endothelial cells decreased GFRP mRNA levels, whereas in contrast GTPCH mRNA and BH4 levels increased. Inhibition of eNOS and GTPCH had no influence on the decrease in GFRP mRNA levels in H 2 O 2 -treated cells, suggesting that H 2 O 2 induces BH4 synthesis through not only induction of GTPCH, but also down-regulation of GFRP, independent of NO and BH4.
Some evidence suggests that GTPCH expression may be down-regulated, and BH4 synthesis thereby reduced, in certain pathological states. In a glucocorticoid-induced rat model of hypertension, GTPCH mRNA levels were reduced, and impaired endothelium-dependent relaxations could be restored by incubating vessels in sepiapterin, suggesting reduced BH4 bioavailability as a cause of eNOS uncoupling [56] . More recent studies in the DOCA (deoxycorticosterone acetate)-salt hypertensive mouse also found that decreased BH4 levels were related to reduced GTPCH activity; supplementation of BH4 or increased BH4 synthesis by adenoviral gene delivery of GTPCH restored BH4 levels and normalized eNOS function [57] . However, these studies have conflicted with the observation that inflammatory cytokines are reported to up-regulate GTPCH expression in endothelial cells [41, 42] , so the importance of altered BH4 synthesis in determining BH4 bioavailability in vascular disease remains uncertain.
An alternative pathway for BH4 synthesis has been documented in bacteria [58] and Drosophila [59] , whereby 6-pyruvoyl-5,6,7,8-tetrahydropterin is converted into sepiapterin by a poorly-defined enzyme termed 'sepiapterin synthase' (Figure 1 ). Evidence for a sepiapterin synthesis pathway in mammals comes from studies of rare patients with SR deficiency, in which sepiapterin levels are elevated in cerebrospinal fluid, suggesting endogenous production of sepiapterin [60, 61] . Certainly, exogenous sepiapterin can be reduced in all cells by SR to BH2 (7,8-dihydrobiopterin) , and further by DHFR (dihydrofolate reductase; EC 1.5.1.3) to form BH4, the BH4 biosynthesis proceeds from GTP via 7,8-dyhydroneopterin triphosphate and 6-pyruvoyl-5,6,7,8-tetrahydropterin. The first and rate-limiting step in the pathway is GTPCH. The following steps are catalysed by the enzymes PTPS and SR. An alternative pathway for BH4 synthesis has been documented whereby 6-pyruvoyl-5,6,7,8-tetrahydrobiopterin is converted into sepiapterin by an enzyme termed 'sepiapterin synthase'. Exogenous sepiapterin can be reduced in all cells by SR to BH2, and further by DHFR to form BH4, the so-called 'salvage pathway'. The principle oxidant species leading to BH4 oxidation to BH2 is peroxynitrite. As a cofactor for the aromatic amino acid hydroxylases in the liver and neurons, but not as a cofactor for NOS, BH4 is converted into tetrahydrobiopterin-4α-carbinolamine, which is recycled to BH4 by the actions of PCD and DHPR.
so-called 'salvage pathway' [62] , that has been exploited by many investigators as an approach to increase BH4 levels by pharmacological supplementation with sepiapterin. However, some data suggest that sepiapterin itself, in high concentrations, may reduce NO bioavailability and increase endothelial superoxide production in vascular disease states, possibly by competing with BH4 for eNOS binding [63, 64] .
BH4 oxidation
Many studies have focused on the potential role of BH4 oxidation to BH2 and other oxidized biopterin species in reducing BH4 bioavailability for eNOS ( Figure 1 ). Preatherosclerotic disease states are associated with increased vascular oxidative stress, particularly superoxide production. Although superoxide can indeed react directly with BH4, the rate constant of this reaction (3.9 × 10 5 M −1 · s −1 ) [65] is many orders of magnitude lower than that for NO with superoxide (6.7 × 10 9 M −1 · s −1 ) [66] . A more likely mechanism for BH4 oxidation is the interaction with peroxynitrite (generated from the interaction between NO and superoxide). Experiments in vitro [67] and ex vivo [68] indicate that peroxynitrite can oxidize BH4 within minutes at physiologically relevant concentrations. EPR (electron paramagnetic resonance) spectroscopy experiments have demonstrated that peroxynitrite oxidizes BH4 to the (non-protonated) BH3 (trihydrobiopterin) radical, and thence to BH2, with a rate constant estimated to be 6 × 10 3 M −1 · s −1 , several-fold higher than reactions between peroxynitrite and ascorbate, glutathione or thiol groups [69] . Oxidation not only directly reduces BH4 bioavailability, but the oxidation products themselves (such as BH2), which have no cofactor activity, may compete with BH4 for binding to eNOS [70] . However, it remains uncertain whether the ratio of BH4 to oxidized biopterins is as important as the absolute BH4 concentration in determining eNOS activity in vivo.
Biopterin recycling
Depending on its cofactor function for the aromatic amino acid hydroxylases compared with the NOS enzymes, BH4 turnover products and regeneration reactions differ. In the aromatic amino acid hydroxylase reactions, BH4 is oxidized to tetrahydrobiopterin-4α-carbinolamine; BH4 is subsequently regenerated in a two-step process. Actions of PCD (pterin 4α-carbinolamine dehydratase; EC 4.2.1.96) lead to the production of the quinonoid dihydrobiopterin intermediate, which is subsequently reduced by DHPR (6,7-dihydropteridine reductase; EC 1.5.1.34) (Figure 1 ). Both enzymes are expressed in mammalian liver [71] , kidney and brain [72] , and mutations in the PCD and DHPR genes are associated with clinical systemic BH4 deficiency and hyperphenylalaninaemia.
As a cofactor for NOS, BH4 is not oxidized to tetrahydrobiopterin-4α-carbinolamine but, during the transfer of electrons to the ferrous-dioxygen complex in the NOS active site, forms BH3.H + (protonated BH3 cation) radical, which is subsequently reduced in the next catalytic cycle by electron transfer from eNOS flavins [65, 73] . Since the BH3.H + radical returns to the BH4 state after each electron transfer step, continuous BH4 regeneration by PCD and DHPR is not a requirement for eNOS activity in endothelial cells.
However, the oxidative loss of BH4 to BH2 in vascular disease states may be partly overcome by a recycling pathway involving DHFR ( Figure 1 ). DHFR plays a central role in folate metabolism, maintaining cellular pools of tetrahydrofolate by reduction of dihydrofolate, but emerging evidence suggests an important function of this enzyme in the recycling of BH2 to BH4. Recent work by Chalupsky and Cai [74] investigated the functionality of endothelial DHFR in cultured bovine aortic endothelial cells. The specific inhibition of DHFR by RNA interference led to markedly decreased endothelial BH4 levels and NO bioavailability. When endothelial cells were exposed to AngII to stimulate superoxide production and a subsequent rise in H 2 O 2 by vascular NADPH oxidase, there was a down-regulation of DHFR expression and a decrease in BH4 levels, and further superoxide generation from uncoupled eNOS. In AngIIstimulated cells, overexpression of DHFR by transfection restored eNOS coupling. These data suggest that DHFR may have an important role on endothelial cell BH4 and NO bioavailability under conditions of oxidative stress.
The regulation of net BH4 bioavailability within the endothelium is likely to result from a complex equilibrium between de novo synthesis, oxidative loss, recycling pathways and biopterin transport between the extracellular and intracellular compartments.
Biopterin transport
The high concentrations of pharmacological BH4 that are required to generate a biological effect in many studies suggest that biopterins do not enter cells merely by passive diffusion. The precise mechanisms for the transport of BH4 into and out of cells have not yet been fully elucidated, but studies, in particular from Hasegawa's group, suggest cell-type-specific aspects of BH4 transport. In the late 1970s, the stereo configuration of BH4 was determined to be 6R-l-erythro-5,6,7,8-tetrahydrobiopterin (6R-BH4) [75, 76] , which led, together with the characterization of both the de novo and the salvage pathways for BH4 synthesis, to the commercial production of 6R-BH4 for the treatment of BH4-deficient patients. As the direct chemical form of the cofactor, 6R-BH4 was regarded as a more rational BH4 supplement than BH2 or sepiapterin, despite the lack of a specific understanding of the mechanisms of cellular transport of biopterins.
The first investigation of biopterin cellular uptake revealed that RBL2H3 cells (rat basophilic leukaemia cells) exposed to sepiapterin elevated the intracellular BH4 concentration much more effectively than exposure to 6R-BH4 [77] . In this experimental setting, BH4 taken up by cells from the medium was immediately oxidized to BH2 and released without being incorporated into the intracellular BH4 pool. These data suggest that regulation of BH4 bioavailability, at least in RBL2H3 cells, requires (1) Intracellular BH4 is generated by endogenous de novo synthesis. (2) The salvage pathway converts exogenous sepiapterin (Sep) into BH4 and recycles BH2 to BH4. (3) Exogenous high-concentration BH4 entering cells from the extracellular space does not appear to mix freely with the endogenous BH4 pool, but becomes rapidly oxidized to BH2 and is exported to the extracellular space. Extracellular BH2 appears to be more readily transported into cells, where it may be converted into BH4 by the salvage pathway. (4) BH4 is susceptible to oxidation directly to BH2 in the extracellular space. BH4 oxidation to BH2 and then controlled reduction back to BH4 in the cell [78] [79] [80] . Nevertheless, a small, but stable, increase in cellular BH4 was observed after 6R-BH4 administration in cell cultures. This increase could be inhibited by treatment with the DHFR inhibitor methotrexate, suggesting that intracellular BH4 accumulation following 6R-BH4 exposure was dependent on DHFR-mediated reduction of BH2 [81] . This hypothesis is supported by the observation that addition of sepiapterin or BH2 to the culture medium efficiently elevates cellular BH4 levels in many different cell types, indicating an involvement of the salvage pathway when extracellular sepiapterin, BH2 and even BH4 are present (Figure 2) . Intracellular BH4 accumulation following sepiapterin administration is thought to be accomplished by at least three functional steps: (i) sepiapterin entry into cells through the plasma membrane; (ii) a forward-driven inout equilibrium of sepiapterin favouring BH4 accumulation by two successive and reversible enzyme reactions catalysed by SR and DHFR; and (iii) BH4 deposition inside the cell due to the relatively low permeability of the cell membrane towards BH4 (with an uptake halftime of approx. 120 min) [82] [83] [84] .
Expanding on these in vitro studies, Hasegawa and coworkers went on to treat mice with 6R-BH4, BH2 or sepiapterin either via the oral (10 mg/kg of body weight) or intraperitoneal route [85] . They found that sepiapterin was able to increase tissue BH4 levels most efficiently, and observed a smaller increase in tissue biopterin levels after oral administration of equivalent doses of 6R-BH4 and BH2. The increased tissue biopterin levels were predominantly comprised of BH4, but consistent with the in vitro experiments, the increase in tissue BH4 was markedly inhibited by pretreatment with 10 mg of methotrexate/kg of body weight before administration of sepiapterin, BH2 or 6R-BH4. Indeed, after methotrexate treatment, the increase in tissue biopterin was almost exclusively comprised of BH2. Supporting the hypothesis that the salvage pathway has a major function in regulating intracellular BH4 levels, the same investigators observed that, despite administering the unnatural diastereomer 6S-BH4 to mice, a large proportion of the increase in tissue BH4 was in the form of the 6R diastereomer [86] . This particular finding provided very strong evidence that accumulating BH4 required the DHFR pathway in which chiral 6S-BH4 is converted (by oxidation) first into achiral BH2 and then reduced (by DHFR) to chiral 6R-BH4 [75, 76] .
However, there may be multiple cell-specific mechanisms for BH4 uptake, since erythrocytes and the epithelial cell line Caco-2 are reported to readily import BH4 directly from the extracellular compartment in a methotrexate-independent fashion. [87] . These mechanisms may be relevant for transport of orally administered BH4 from the gastrointestinal tract and for the renal excretion of BH4.
The studies by Hasegawa's group have provided intriguing insights into the pharmacokinetics and biodistribution of BH4 as a therapeutic agent; however, the nature of possible biopterin receptors/transporters remains unknown. A more complete understanding of cellular biopterin transport, and the ability to modulate this, would open new therapeutic approaches for the treatment of endothelial dysfunction.
MECHANISMS OF eNOS REGULATION BY BH4
Increased generation of ROS (reactive oxygen species) and a shift in balance from NO to ROS signalling represent common features among different vascular disease states. Several oxidase systems contribute to increased oxidative stress, notably the NADPH oxidases [88] . However, eNOS itself can generate superoxide under certain pathophysiological conditions. In vitro experiments using EPR spectroscopy have demonstrated that BH4 both stabilizes and donates electrons to the ferrous-dioxygen complex in the oxygenase domain, as the initiating step of l-arginine oxidation and NO synthesis [70, 73, 89] . When BH4 is limiting, electron transfer from eNOS flavins becomes uncoupled to l-arginine oxidation, the ferrous-dioxygen complex dissociates and superoxide is produced from the oxygenase domain [90] [91] [92] (Figure 3) . Superoxide generation by eNOS has been observed in a variety of experimental and clinical vascular disease states, including diabetes [32, 93] , cigarette smoking [94] , hypertension [95] , chronic nitrate tolerance [96] and overt atherosclerosis [97] . eNOS uncoupling in vascular disease may have a profound effect on NO bioavailability because NO production is reduced, and superoxide production is increased, leading to further reductions in NO bioactivity by scavenging and increasing oxidative stress within endothelial cells by formation of peroxynitrite. It is likely that NOS must assemble in its dimeric form for catalytic activity, whether producing NO or superoxide, and there may be a role for BH4 in stabilizing eNOS dimers. A zinc ion is tetrahedrally co-ordinated to pairs of cysteine residues at the dimer interface, one pair from each subunit, close to the BH4-binding site [98] . Site-directed mutagenesis studies indicate that the cysteine residues are critical for locating BH4 in its binding site and maintaining NO production by eNOS [99] . Recent evidence suggests that disruption of the zincthiolate complex by peroxynitrite leads to loss of BH4 from the active site, enzymatic uncoupling and destabilization of eNOS dimers [100] . Recombinant enzyme expression experiments [101] [102] [103] and endothelial cell culture studies [104] also indicate that BH4 indeed promotes eNOS dimerization, protein stability and NO synthesis. Accordingly, BH4 may have independent, but complementary, roles in both the physical stabilization of eNOS in its active dimeric form and in its participation in the NOS catalytic reaction.
BH4 AND VASCULAR DISEASE
A range of in vitro approaches, in vivo pharmacological experiments, genetically modified mouse models and clinical studies have been employed to explore the role of BH4 on eNOS function in the context of vascular diseases, including diabetes, hypertension, experimental vascular injury and hypercholesterolaemia. On the basis of this experimental evidence, endothelial BH4 bioavailability has emerged as a rational therapeutic target in vascular disease states.
Diabetes
Early in vitro evidence that altered glucose metabolism may affect BH4 bioavailability came from studies in which endothelial cells isolated from the spontaneously diabetic BB rat were found to have reduced BH4 levels compared with cells from control strains, which were associated with reduced NO production despite normal eNOS protein levels [105] . Augmented BH4 availability by sepiapterin supplementation was able to restore this deficiency.
Cai et al. [104] used adenovirus-mediated gene transfer of GTPCH to investigate whether augmented BH4 biosynthesis in hyperglycaemic human aortic endothelial cells would be sufficient to rescue eNOS activity and dimerization. Exposure of these cells to high glucose (30 mmol/l) induced an increase in total eNOS protein, but a shift from the dimeric to the inactive monomeric form, a reduction in intracellular BH4 levels, a reduction in net NO synthesis and increased superoxide generation from uncoupled NOS. Transduction of hyperglycaemic cells with GTPCH [but not GFP (green fluorescent protein) control] markedly augmented BH4 levels, restored eNOS dimerization, increased NO synthesis and suppressed superoxide generation, indicating a restoration of eNOS coupling.
Insulin-resistant fructose-fed rats exhibit increased vascular superoxide production, oxidative degradation of BH4 in the aorta, reduced eNOS activity and impaired endothelium-dependent vascular relaxations compared with controls [106, 107] . Dietary BH4 supplementation or incubation of aortic rings in BH4 solution [106] prevented these abnormalities [107] . Similarly, streptozotocininduced diabetes in rats and hyperglycaemia in spontaneously diabetic (db/db knockout) mice resulted in impaired endothelium-dependent relaxations of vascular rings, which could be restored acutely by incubation with BH4 [108] .
However, these in vivo experimental interventions have involved short-term pharmacological supplementation of high-dose BH4, and the importance of low dose persistent augmentation of BH4 levels in maintaining eNOS coupling in diabetes was uncertain. These questions have been addressed by the generation of a transgenic mouse model of increased vascular BH4 synthesis, in which human GTPCH expression is targeted to the vascular endothelium under the control of the mouse Tie-2 promoter (termed GCH-Tg mice) [109] . Overexpression of GTPCH in GCH-Tg mice was sufficient to increase BH4 levels specifically in vascular tissues. Experimental streptozotocin-induced diabetes did not have a major impact on total vascular biopterins, but increased vascular oxidative stress, leading to oxidation of BH4, forming BH2 and biopterin. In wild-type littermates, this oxidation resulted in almost undetectable levels of BH4 but, in GCH-Tg mice, modest BH4 levels were maintained despite increased vascular oxidative stress, which was associated with greatly decreased superoxide production from the endothelium. Depletion of BH4 and increased endothelial superoxide production in diabetic wild-type mice was associated with deficient NO-mediated endothelial function, which was prevented by the maintenance of endothelial BH4 levels in diabetic GCH-Tg mice [109] . These findings support the pivotal role of BH4 in maintaining eNOS coupling, even in diabetic vascular oxidative stress, and validate pharmacological strategies of BH4 supplementation.
In clinical studies, an acute oral glucose challenge causes endothelial dysfunction in patients with Type 2 diabetes and insulin resistance [110, 111] as well as in healthy subjects [112, 113] . Ihlemann et al. [114] used this approach in healthy subjects to cause transient impairment of endothelial function, probably due to increased oxidative stress. Using venous occlusion plethysmography to measure forearm blood flow, they found that acute 6R-BH4 infusion restored endothelial dysfunction. This was probably due to a specific effect on eNOS activity rather than a non-specific antioxidant effect of BH4, since infusions of the inactive diastereomer 6S-BH4, which possesses equipotent antioxidant properties, had no effect. Similar experiments in patients with Type 2 diabetes demonstrated a reversal of endothelial dysfunction following BH4 infusion, via an NO-dependent mechanism [115] .
Systemic and pulmonary hypertension
Since blood pressure is partly dependent on NO-mediated regulation of vascular tone, the BH4-eNOS interaction may be a relevant therapeutic consideration in hypertension. Various animal models have been developed to explore this hypothesis. In spontaneously hypertensive rats, pharmacological BH4 supplementation has been shown to improve endothelial dysfunction [116, 117] . Oral BH4 treatment also prevented the development of hypertension and myocardial hypertrophy induced by AngII infusion in rats, which was associated with decreased oxidative and nitrosative stress [118] . Taylor et al. [119] investigated the role of uncoupled NOS in the generation of superoxide in the kidneys of Dahl salt-sensitive rats, and observed that a decreased BH4 to BH2 ratio was associated with eNOS uncoupling [119] . However, the requirement to use a control rat strain rather than littermates for comparisons in this model may limit the interpretation of these findings. Further evidence for a direct role of BH4 in regulating eNOS in hypertension comes from a DOCA-salt model of hypertension in mice, where increased aortic superoxide production, BH4 oxidation and eNOS uncoupling could be prevented by oral BH4 supplementation [95] .
The characterization of the hyperphenylalaninaemic (Hph-1) mouse has provided additional mechanistic insight into eNOS regulation by BH4. The Hph-1 mouse, generated by ENU (N-ethyl-N-nitrosourea) mutagenesis, exhibits systemically reduced levels of GTPCH expression and (50-80 %) decreased BH4 synthesis. The ENU point mutation has been mapped to a congenic interval of 1.6-2.8 Mb, encompassing the GCH1 gene, and is likely to affect the regulation of GCH1 expression [120] . Initial studies of the systemic vascular phenotype of the Hph-1 mouse indicated systemic hypertension, increased vascular oxidative stress and reduced eNOS activity, although these findings should be interpreted with caution since control mice were from a matched wild-type strain rather than littermates [121] and, indeed, a subsequent study was not able to demonstrate the systemic hypertensive phenotype in these mice [122] .
The role of BH4 in regulating eNOS function in the pulmonary vasculature has been explored. Endothelial dysfunction is implicated in the pathogenesis of pulmonary hypertension, but the mechanisms remain poorly understood. Through potent vasodilator and antiproliferative effects on vascular smooth muscle cells, NO appears critical in maintaining normal pulmonary vascular tone and structure [123, 124] . Mice deficient in eNOS are more sensitive to hypoxia-induced pulmonary hypertension [125, 126] , and pulmonary gene transfer of eNOS is partially protective [127] . Paradoxically, mice with hypoxiainduced pulmonary hypertension have increased eNOS protein levels, without a concomitant increase in NO bioactivity [128, 129] . Increased superoxide production from NADPH oxidase and xanthine oxidase is observed in some experimental models of pulmonary hypertension [130, 131] , and markers of oxidative stress are increased in patients with pulmonary hypertension [132, 133] . These observations suggest that altered NO synthesis, and increased superoxide production, may play central roles in the pathogenesis of pulmonary hypertension, but the importance of NOS regulation by BH4 remained unknown. Khoo et al. [134] used a range of genetically modified mouse lines to address this question. In the Hph-1 mouse with deficient BH4 biosynthesis, BH4 deficiency caused pulmonary hypertension, even in normoxic conditions, and greatly increased susceptibility to hypoxia-induced pulmonary hypertension. Independent studies confirmed this pulmonary systemic phenotype in the Hph-1 mouse [122] . Importantly, augmentation of endothelial BH4 synthesis in GCH-Tg mice, by targeted transgenic overexpression of GTPCH, prevented hypoxia-induced pulmonary hypertension [134] . Furthermore, specific augmentation of endothelial BH4 in Hph-1 mice by crossing with GCH transgenic mice rescued pulmonary hypertension induced by systemic BH4 deficiency. Lung BH4 availability controlled pulmonary vascular tone, right ventricular hypertrophy and vascular structural remodelling, in a dose-dependent manner, in both normoxia and hypoxia. These effects of BH4 were mediated through the regulation of NO compared with superoxide synthesis by endothelial NOS. These observations highlight BH4 regulation of eNOS as a common and fundamental mechanism in vascular remodelling in both the systemic and pulmonary circulation.
As yet, there are no published clinical studies of BH4 therapy in human systemic or pulmonary hypertension. This is partly related to the lack, until very recently, of a convenient stable oral formulation of BH4 to allow long-term oral therapy in these patient populations.
Hypercholesterolaemia
Hypercholesterolaemic ApoE-KO mice have been used in a range of studies to explore the role of BH4, eNOS and NO in vascular homoeostasis, endothelial dysfunction and atherosclerosis. ApoE-KO mice exhibit impaired endothelium-dependent vascular relaxations and increased vascular superoxide production; both abnormalities can be reversed by in vitro incubation of vessels with sepiapterin [68] . A recent study [135] investigated whether BH4 supplementation was sufficient to modulate atherosclerosis in ApoE-KO mice fed a high-fat diet. Oral BH4 administration improved endotheliumdependent vascular relaxation and, after 10 weeks of a high-cholesterol diet, reduced aortic root plaque area by 25 %. Furthermore, BH4 treatment reduced vascular superoxide production, indicating that BH4 supplementation in these hypercholesterolaemic conditions appeared able to preserve NOS coupling and endothelial function in the setting of atherosclerosis.
Studies using GCH-Tg mice crossed with ApoE-KO mice showed that endothelium-specific overexpression of GTPCH was sufficient to modestly increase vascular BH4 levels in atherosclerosis [136] . Uncoupled eNOS contributed to endothelial superoxide production in aortas of ApoE-KO mice, but eNOS coupling was preserved by increased vascular BH4 levels in aortas of ApoE-KO/GCH-Tg mice, as demonstrated by increased aortic cGMP levels and preserved endothelium-dependent vascular relaxations. Importantly, the preservation of endothelial function by GTPCH overexpression in ApoE-KO mice reduced atherosclerosis progression. These results validate the pharmacological approaches of other studies and confirm a specific effect of BH4 in NOS regulation in atherosclerosis.
Interestingly, transgenic endothelial overexpression of eNOS alone in ApoE-KO mice leads to accelerated atherosclerosis, associated with increased vascular superoxide production [11] . This is, in part, related to eNOS uncoupling, resulting from an imbalance between reduced vascular BH4 levels and increased transgenic eNOS protein. However, dietary BH4 supplementation in this model reduced superoxide production and restored NO synthesis. These results indicate that increased eNOS protein alone is insufficient to maintain NO synthesis in hypercholesterolaemia and that adequate BH4 levels are essential in preventing enzymatic uncoupling. In contrast with this study [11] , van Haperen et al. [137] have reported that atherosclerotic lesion size was reduced by eNOS overexpression after crossing their individually generated eNOS transgenic mice with ApoE-KO mice. The different results in these two studies were considered to be related to differences in blood pressure and plasma cholesterol levels.
Regarding vascular BH4 levels in ApoE-KO mice, contrasting findings have been reported. Although some investigators have observed reduced BH4 levels in the aortas of ApoE-KO mice compared with wild-type control mice [11] , a recent study by d'Uscio et al. [138] has reported increased vascular biosynthesis of BH4 in ApoE-KO mice. Choice of diet used in these studies may partly account for these differences. However, ex vivo removal of the endothelium almost eliminated BH4 in the aorta of wild-type mice, but this intervention barely affected BH4 levels in ApoE-KO mice, suggesting that a major component of increased BH4 synthesis is localized in the vascular media of ApoE-KO mice, possibly derived from macrophages in atherosclerotic plaques [138] . This finding emphasizes the importance of the cellular compartmentalization of BH4, with respect to eNOS regulation in the endothelium compared with regulation of other NOS isoforms, such as iNOS, within inflammatory cells in the vascular wall.
Acute administration of BH4 has been shown to improve endothelial function of patients with hypercholesterolaemia [139] . However, as a similar limitation to clinical studies in hypertension, longer term supplementation with BH4 in hypercholesterolaemia has been challenging because of a lack of a stable and convenient oral formulation. Nevertheless, Hurlimann et al. [140] studied 22 patients with hypercholesterolaemia and no overt macrovascular disease in a randomized double-blind fashion to a 4 week treatment with BH4 (400 mg, twice daily). BH4 was stored as a powder at −20
• C and freshly dissolved before each administration. Age-matched normocholesterolaemic volunteers served as controls. Endothelium-dependent vasorelaxation in hypercholesterolaemic patients was reduced compared with controls, as assessed by forearm venous occlusion plethysmography and intra-arterial infusion of acetylcholine. BH4 restored endothelium-dependent vasodilatation, but had no effect on endothelium-independent vasodilatation, as assessed by infusion of the NO donor SNP (sodium nitroprusside). In addition, serum 8-epi-PGF 2α (8-epiprostaglandin F 2α ) levels, a marker of oxidative stress, were significantly reduced in the BH4 treatment group only. These data indicate that hypercholesterolaemic endothelial dysfunction and oxidative stress can be ameliorated by chronic treatment with BH4.
Vascular injury
Mechanical injury of blood vessels during clinical procedures, such as angioplasty and coronary artery bypass grafting, provokes a vascular repair response characterized by smooth muscle cell proliferation leading to intimal hyperplasia. Endothelial cell loss and regeneration may be important determinants of the response to vascular injury, and NO is a key regulator of endothelial cell and EPC (endothelial progenitor cell) function, but the mechanisms that regulate eNOS in endothelial regeneration have been unclear. Using a femoral artery wire injury model, Wang et al. [141] investigated the effects of vascular BH4 deficiency in Hph-1 mice on neointimal formation. There was a marked increase in intimal hyperplasia following vascular injury in Hph-1 mice, which was associated with increased superoxide production and decreased eNOS activity. In addition, macrophage cell numbers in the adventitia were significantly increased. These features could be restored after BH4 treatment.
Ali et al. [142] have reported that augmenting levels of BH4, by endothelium-targeted overexpression of GTPCH, reduces intimal hyperplasia in experimental vein grafts in ApoE-KO mice. The underlying mechanisms involved enhanced repopulation of the vein graft by recipient-derived endothelial cells and increased survival of donor-derived endothelial cells within the graft [142] . Endothelial overexpression of GTPCH increased EPC numbers and increased proliferative capacity of endothelial cells, which was associated with reduced superoxide generation from uncoupled NOS. These observations indicate that endothelial BH4 availability modulates intimal hyperplasia following vascular injury via accelerated endothelialization, a process regulated through eNOS coupling.
Vascular aging
Aging is a significant contributor to the development of cardiovascular diseases. A clinical marker of the ageassociated increase in vascular risk is a reduction in endothelium-dependent vascular relaxation [143, 144] , probably mediated by oxidative stress [145, 146] . Regular exercise in older adults is associated with reduced oxidative stress and preservation of endothelium-dependent vascular relaxation [145, 146] . The mechanisms by which aging impairs vascular function are not fully elucidated, but may involve eNOS regulation by BH4. Eskurza et al. [147] therefore examined the role of oral BH4 supplementation in sedentary and habitually exercising older adults and found that BH4 augments endothelial function in sedentary older adults, but not in habitually exercising older adults or in young sedentary adults. Consistent with these findings, Higashi et al. [148] have shown that acute BH4 infusions improved aging-related impairment of endothelium-dependent vasodilation through an increase in NO production. This suggests that reduced BH4 bioactivity may be a key mechanism involved in the impairment of peripheral conduit artery vasomotor function with aging.
Homocysteine, folate and BH4
Plasma levels of total homocysteine [149] and folate [150] are related to cardiovascular risk [149] and endothelial dysfunction [151] [152] [153] . Whether the increased risk is directly mediated by homocysteine or if plasma homocysteine is merely a marker for a related pathophysiological process remains controversial. Initial clinical trials have suggested that lowering total homocysteine with folate may retard atherosclerosis [154] , but three recent larger trials in patients with stroke [155] , myocardial infarction [156] or stable coronary artery disease [157] found that folate treatment did not improve clinical outcome. Some evidence suggests that mechanisms other than homocysteine-lowering may be important factors in the relationship between folate and atherosclerosis. Studies have reported beneficial effects of folate treatment on endothelial function in patients with advanced atherosclerosis that are discordant with changes in plasma homocysteine [158] . In particular, 5-MTHF (5-methyltetrahydrofolate), the circulating form of folate, appears to be most strongly associated with endothelial function, independent of plasma homocysteine levels [159] . Indeed, intra-arterial infusion of 5-MTHF improved flow-mediated dilatation in patients with coronary artery disease before any detectable reduction in plasma homocysteine [153] . Since 5-MTHF is a reduced form of folate that does not require conversion by DHFR, some direct effects may be attributable to redox mechanisms that are not seen when oral folate is used to increase plasma folate levels.
The mechanisms by which 5-MTHF regulates eNOS activity are incompletely understood. In NOS enzymereconstitution experiments, 5-MTHF had no effect on enzymatic activity when BH4 was absent but, when eNOS was partially restored with BH4 in vitro and in cultured endothelial cells, 5-MTHF enhanced NO synthesis and reduced superoxide generation from eNOS [160] . Data from structural computer modelling suggest that 5-MTHF can bind to the eNOS active site and potentially participate in the NO catalytic reaction [152] , although this hypothesis has not yet been confirmed by definitive experimental data from crystallography or enzyme-binding kinetic studies.
A further mechanism by which folate may be involved in NOS regulation is by protection of BH4 from oxidative loss. Antoniades et al. [161] have recently investigated the importance of 5-MTHF treatment on vascular function in patients with coronary artery disease. Vascular superoxide and peroxynitrite production and vasomotor responses were measured in saphenous veins and internal mammary arteries obtained from 117 patients undergoing coronary artery bypass graft surgery. NO-mediated endothelium-dependent vasomotor responses were significantly improved and vascular superoxide levels were decreased both in isolated vessels incubated ex vivo with 5-MTHF and after intravenous infusion of 5-MTHF before vessel harvest compared with placebo-treated patients. Indeed, 5-MTHF treatment reversed eNOS uncoupling in these vessels, increased eNOS dimer stability and enhanced eNOS activity. These effects were not explained by changes in plasma total homocysteine and plasma biopterin levels in vivo. Rather, 5-MTHF increased vascular BH4 and the BH4/total biopterin ratio.
In vitro experiments have shown that 5-MTHF acts as a strong scavenger of peroxynitrite, demonstrated in other studies to be the major chemical species causing oxidation of BH4 to BH2 [67] [68] [69] . This study suggested that 5-MTHF has beneficial effects on endothelial function in atherosclerosis through the reduction of vascular peroxynitrite-mediated BH4 oxidation and maintenance of eNOS coupling. However, other studies using rabbit aortic rings and porcine aortic endothelial cells have shown no effect on BH4 levels following incubation in 5-MTHF nor any protective effect of 5-MTHF on BH4 oxidation in vitro, despite enhancing NO bioavailability in experimental BH4 deficiency [162] . Further studies are required to clarify the mechanisms of folates in regulating eNOS in vascular disease.
eNOS/BH4 stoichiometry and eNOS uncoupling
Previous in vivo studies have focused on the potential role of BH4 oxidation, to BH2 and other biopterin species, in reducing BH4 bioavailability in pre-atherosclerotic disease states [9, 57, 65] . However, the mechanistic relationship between eNOS and BH4 had not been investigated in the absence of pathological oxidative stress, where multiple inflammatory and redox pathways are implicated, and it has remained unclear whether eNOS uncoupling alone was sufficient to initiate BH4 oxidation. To address this question, Bendall et al. [163] crossed the GCH-Tg mouse (demonstrating increased endothelial BH4 synthesis) with a mouse overexpressing eNOS in the endothelium (eNOS-Tg) to generate mouse models with graded alterations in both endothelial BH4 and eNOS levels. eNOS protein levels were markedly elevated in both eNOS-Tg and eNOS/GCH-Tg mice, but not in GCH-Tg mice. Endothelium-specific overexpression of GTPCH was sufficient to increase vascular BH4 levels both in aortas of GCH-Tg and eNOS/GCH-Tg mice, whereas BH4 levels were depleted in aortas of eNOS-Tg mice. This increase in BH4 was sufficient to augment vascular eNOS enzymatic activity even in GCH-Tg mice. Importantly, the increase in endothelial BH4 in eNOS/GCH-Tg mice enhanced further eNOS activity and NO bioavailability compared with eNOS-Tg mice. The discordance between endothelial BH4 and eNOS protein in eNOS-Tg mice resulted in uncoupled eNOS and increased NOS-derived superoxide production both in tissue lysates and intact aorta. However, increased vascular BH4 in eNOS/GCH-Tg mice was sufficient to restore eNOS coupling, increase NO production and reduce eNOS-dependent superoxide production. Overall these results show that eNOS coupling is directly related to eNOS-BH4 stoichiometry even in the absence of a vascular disease state, highlighting endothelial BH4 availability as a pivotal regulator of eNOS activity and enzymatic coupling in vivo.
THERAPEUTIC PROSPECTS FOR BH4
What are the prospects for vascular disease therapies that target BH4-dependent eNOS function? Several studies have shown that ascorbate (vitamin C) may be important in maintaining BH4 levels in the setting of vascular oxidative stress. In small clinical studies, high-dose ascorbate supplementation improves endothelial dysfunction in smokers [164] , in subjects with hypercholesterolaemia [165] and in patients with diabetes mellitus [166, 167] or overt coronary artery disease [168, 169] . However, large scale randomized clinical trials of ascorbate supplementation with several years of follow-up have shown no benefit in terms of hard vascular end points [170] . This disappointing finding could be explained by inadequate ascorbate doses in this particular study, perhaps initiated too late in the progression of atherosclerosis for significant clinical benefit to be observed.
High-dose pharmacological supplementation of BH4, given as acute intravenous infusions, is clearly not practical as a therapy for chronic vascular disease states. The few short-term studies of oral BH4 therapy in atherosclerosis have been limited by the pharmaceutical preparation of BH4, which has required light-protected storage at − 20
• C to prevent BH4 oxidation. However, a recent new biophysical formulation of BH4 has been developed which is stable as a tablet at room temperature for up to 2 years. Pre-clinical and clinical studies of chronic oral BH4 supplementation using this preparation are currently underway in a range of vascular disease states.
CONCLUSIONS
Current research indicates that maintaining adequate BH4 levels in the endothelium is likely to be critical in regulating the balance of NO and superoxide synthesis by eNOS in vascular disease. Strategies to maintain vascular BH4 availability may include measures to increase BH4 biosynthesis or to reduce oxidative degradation. Despite significant recent insights into the molecular interactions between BH4 and eNOS regulating endothelial biology, a number of important questions remain unanswered. Pharmacokinetic data from Hasegawa's group discussed in this review suggest that biopterins do not enter cells merely by passive diffusion; however, the nature of a possible biopterin receptor or transporter is currently unknown. A better understanding of cellular biopterin transport would open new therapeutic approaches for endothelial dysfunction in vascular disease. An additional question concerns the role of the BH4 recycling pathway (mediated by DHFR) in maintaining BH4 concentrations in the vascular endothelium: this pathway may represent an important new therapeutic target.
It is likely that the development of new mouse models with tissue-specific overexpression or deficiency of enzymes relevant to biopterin metabolism will continue to provide important mechanistic insight into the role of BH4 in regulating eNOS function. The recent developments in BH4 pharmaceutical formulations will help to translate these findings into clinical trials of BH4 supplementation therapy in vascular disease.
